We are now embarking on the metamorphosis of biomedical research laboratories. Advancements in technology, greater understanding of the mechanism of disease, automation, and market forces drive the transformation of traditional research laboratories. How does this impact the role of the biomedical laboratory scientist? How does this impact the design of laboratory spaces? Join us for an interactive discussion on technology, collaboration, and other trends in laboratories and their implication on space.
|
Presentations
|
| |
Future Trends in the Design of Biomedical Research Laboratories
Philip Plottel Founder and CEO, Telshire LLC
Formerly Global Head, Design and Engineering, Novartis Institutes for Biomedical Research
Biopharmaceuticals are increasingly focusing research investment on personalized medicine and "rare" diseases. The increase in data, advances in technology, and societal pressures are driving change in biomedical research labs. Current designs are rooted in middle age alchemy, education traditions, and outdated practices. Learn how innovation in laboratories using 21st century paradigms will advance knowledge and facilitate the discovery of new medicines.
|
| |
Impact of Lab Automation
Ira Hoffman, Managing Director,
HighRes Biosolutions
The business of biopharmaceuticals creates huge demands to discover new drugs and bring them to market faster. Historically, laboratory work involved repetitive manual processes. The integration of robotics into the laboratory allows for continuous operation, reduces error, generates huge quantities of data, and allows for more sophisticated experimentation. Learn how robotics changes the role of the scientist and the requirements of laboratories.
|
| |
> back to top |
|
Speakers
|
 |
Philip Plottel
Founder and CEO, Telshire LLC
Formerly Global Head, Design and Engineering
Novartis Institutes for Biomedical Research
Phil is the founder and CEO of Telshire LLC a boutique consultancy with a mission to assist companies and institutions understand, strategize and implement their life science real estate and facility needs. Prior to Telshire, Phil was the Global Head for Design and Engineering and Head of Cambridge Real Estate, Engineering and Construction with the Novartis Institutes for Biomedical Research (NIBR) where he established the NIBR presence in Cambridge by acquiring over one million square feet of laboratory and office space. Phil procured and managed the architect, engineering and construction teams and oversaw the design and construction of sustainable and LEED certified facilities. Phil spent a year as the Program Executive for Novartis’ Shanghai Campus; authored guidelines for the “laboratory of the future”; and implemented energy conservation measures that led to a 10% absolute decrease in NIBR’s energy usage.
Phil is a licensed Professional Engineer in New York State and holds a Master of Business Administration from the Yale University School of Management, a Master of Science in Engineering from the University of Texas at Austin and Bachelor of Science from the Columbia University’s Fu Foundation School of Engineering and Applied Sciences.
> back to top
|
 |
Ira Hoffman
Managing Director
HighRes Biosolutions
Ira Hoffman is the Managing Director at HighRes Biosolutions where he leads project management, sales and support. Prior to joining HighRes, Ira was Director of Research and Development at Freedom Sciences, where he developed innovative robotic hardware for people with limited mobility. Before that he was at Merck for six years, where he led many successful projects for various screening groups at Merck, including the integration of systems capable of screening 1 million samples in less than a week, the development of an enterprise data warehouse for capturing and reporting screening results, the development of analytical approaches for combining screening results with chemical structure, and the implementation of real-time, automated quality control monitoring of screening processes.
Ira graduated with a BS in Physics and Mathematics from the University of Vermont, and an MS in Computer Science from Villanova University.
> back to top
|
|
Panelists
|
| |
Paul Jansenwillen
Workplace Solutions R+D Lead
Pfizer Inc.
For the last several years, Paul is supporting Pfizer R&D with workplace strategies. His 21 year experience in the biopharmaceutical industries includes working in the design, engineering, construction and validation of life science facilities initially as International Projects director with Bovis Lend Lease Pharmaceutical (formerly TANVEC), then as UK Operations director with Washington International Biopharm Group, and lately as Managing Director with SciTech Engineering Ltd. His concept design and project engineering management experience encompasses most types of pharmaceutical and biotechnology facilities from discovery research to packaging and distribution.
A process architect by background, Paul has been responsible for the Site Master planning and led the concept design of major R+D and manufacturing facilities for many of the major pharmaceutical companies such as; Amgen, Abbott Laboratories, GlaxoSmithKline (R+D, Pharmaceutical, Consumer Health and Biologicals), Janssen Pharmaceutica (J&J), Schering Plough (Merck), Pfizer, Wyeth (Pfizer). In addition, he has worked on numerous projects for CMO organisations and Generics manufacturers such as Lonza, Covance and TEVA.
Geographically, his work has been executed in the UK, Europe (Belgium, Finland, France, Germany, Hungary, Italy, and The Netherlands), Asia (China and Korea) and the US (CA, CT, MA and MI).
Over this period he has given numerous presentations to the Industry, and to professional bodies, to include:
Over the last 10 years, Paul has been at the forefront of the design of future – proofed ‘Flexi-Labs’ for companies such as GlaxoSmithKline (DRAF facilities in the UK + US) and Pfizer (B530 + iSpace) and has lately begun designing ‘Flex Factory’ manufacturing projects using single-use / disposable process technologies for biotech bulk drug substance and fill + finish facilities.
> back to top
|
.jpg) |
Kevin Carmody
Senior Manager Engineering
Astra Zenica
Kevin Carmody obtained his B.S.M.E. from the Lowell Technological Institute in Massachusetts. During the course of his career, Kevin has held a variety of plant engineering positions in process and manufacturing facilities. He has been engaged in the biotech and pharmaceutical industries for the past 20 years, and he presently serves as the Engineering Manager for AstraZeneca R&D Boston. He is responsible for engineering activities at the site including discovery and infrastructure capital projects, site master planning, laboratory space planning and design, and the site basis of design. Kevin has also represented AZUS in global efforts to further develop common design guidelines for laboratory buildings and HVAC systems.
Kevin has been with AstraZeneca since 1996, when he joined the former Astra Research Center Boston. During his tenure, he has been instrumental in the design, construction, and start-up of the company’s award winning R&D facility and follow-up expansion projects.
Kevin served as an integral part of the international project team responsible for the development of the AstraZeneca R&D Boston building program and the selection of professional and construction services. He was directly responsible for programming, MEP design effort, owner procured equipment, and laboratory casework system.
> back to top
|
 |
John Primeau
Head, Chemistry, Infection IMed Boston,
Astra Zeneca
With over 26 years of experience in Drug Discovery, John began his career as a medicinal chemist and advanced into discovery line leadership after leading drug discovery and development teams. He joined AZ Boston in 2000 to focus on the pursuit of new and essential antibacterial agents.
He is quoted as saying, “I was drawn by the outstanding talent that was already in place at AZ Boston, the commitment of AstraZeneca to antibacterial science and the ready access to the talent in the Boston area”.
In addition to his responsibilities within the Infection group in Boston, he has participated in laboratory planning at AstraZeneca and is the section editor for Annual Reports in Medicinal Chemistry (Infectious Diseases)
> back to top
|
|
Click to View Recorded Presentations 
